70610-87-6

Basic information

• Product Name: 2-BROMOOCTANOIC ACID
• Synonyms: A-BROMOCAPRYLIC ACID;ALPHA-BROMOCAPRYLIC ACID;2-BROMOCAPRYLIC ACID;2-BROMO-N-OCTANOIC ACID;2-BROMOOCTANOIC ACID
• CAS NO: 70610-87-6
• Molecular Formula: C8H15BrO2
• Molecular Weight: 223.11
• EINECS: 220-079-7
• Mol File: 70610-87-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 140 °C5 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.278 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000941mmHg at 25°C
• Refractive Index: n20/D 1.471(lit.)
• CAS DataBase Reference: 2-BROMOOCTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOOCTANOIC ACID(70610-87-6)
• EPA Substance Registry System: 2-BROMOOCTANOIC ACID(70610-87-6)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• F: 8-10
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 70610-87-6(Hazardous Substances Data)

Usage

General Description

2-Bromooctanoic Acid, also known as Octanoic Acid, 2-Bromo-, is a chemical compound often used in scientific research and industrial applications. 2-BROMOOCTANOIC ACID has a distinctive fatty acid structure crucial in the production of pharmaceuticals, polymers, and in organic synthesis. It is characterized by its medium-length carbon chain comprising eight carbons, with a bromine atom attached to the second carbon and a carboxylic acid group (-COOH) at one end. Due to the presence of the bromine atom, 2-Bromooctanoic Acid is reactive, making it useful in various organic transformations. However, its reactivity and corrosiveness necessitate safe handling and storage procedures to prevent harm to humans and the environment.

InChI:InChI=1/C8H15BrO2/c1-2-3-4-5-6-7(9)8(10)11/h7H,2-6H2,1H3,(H,10,11)

Upstream product

• 124-07-2 Octanoic acid 
• 78389-69-2 (2-Bromo-octyloxy)-trimethyl-silane 
• 111-64-8 n-octanoic acid chloride 
• 2984-50-1 1,2-Epoxyoctane 
• 3974-36-5 2-n-hexyl malonic acid 
• 644-90-6 2-aminooctanoic acid 
• 2623-82-7 2-bromooctanoic acid 

Downstream Products

• 102006-16-6 2-Benzaminooxy-octansaeure-⁽¹⁾ 

Relevant articles and documents

Enantioselective protonation of α-hetero carboxylic acid-derived ketene disilyl acetals under chiral ionic Bronsted acid catalysis

Highly enantioselective protonation of α-halo and alkoxy carboxylic acid-derived ketene disilyl acetals is achieved by using P-spiro chiral diaminodioxaphosphonium barfate as a Bronsted acid catalyst, where the enantiofacial discrimination by the catalyst mainly stems from the recognition of the electronic difference between two substituents on the ketene disilyl acetal.

Synthesis and biological evaluation of novel N-α-haloacylated homoserine lactones as quorum sensing modulators

Novel N-α-haloacylated homoserine lactones, in which a halogen atom was introduced at the α-position of the carbonyl function of the N - acyl chain, have been studied as quorum sensing (QS) modulators and compared with a library of natural N - acylated homoserine lactones (AHLs). The series of novel analogues consists of α-chloro, α-bromo and α-iodo AHL analogues. Furthermore, the biological QS activity of the synthetic AHL analogues compared to the natural AHLs was evaluated. Halogenated analogues demonstrated a reduced activity in the Escherichia coli JB523 bioassay, with the α-iodo lactones being the less active ones and the α-chloro AHLs the most potent QS agonists. Most of the α-haloacylated analogues did not exhibit a significant reduction when tested in the QS inhibition test. Therefore, these novel analogues could be utilized as chemical probes for QS structure-activity studies.

N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-α converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R2and R3form a heterocyclic ring and A is S, S(O), or S(O)2, and R1and R4are defined herein.